I am pleased to submit an original research article entitled “REAL-WORLD CLINICAL OUTCOMES ASSOCIATED WITH CANAGLIFLOZIN IN PATIENTS AGED 65 YEARS AND OLDER WITH TYPE 2 DIABETES MELLITUS IN SPAIN: THE OLD REAL-WECAN STUDY” for consideration for publication in theInternational Journal of Clinical Practice.

We have previously reported the effectiveness of canagliflozin 100 and the switch to canagliflozin 300 from a prior SGLT-2i in patients with T2DM in a real world setting (Gorgojo-Martínez JJ, Gargallo-Fernández MA, Galdón Sanz-Pastor A, Antón-Bravo T, Brito-Sanfiel M, Wong-Cruz J. Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. J Clin Med. 2020; 9: 2275 ), now this manuscript show the subanalysis results of our prior study to assess the effectiveness and safety of canagliflozin in patients aged> 65 years.

Given the scarce data about effectiveness of canagliflozin in older patients, and the lack of data about switching to canagliflozin 300 from any SGLT-2i in the increasing number of T2DM patients older than 65 years, we believe that this manuscript is appropriate for publication by